Deborah Dunsire has been a director of Alexion since January 2018. Dr. Dunsire served as President and Chief Executive Officer of Millennium Pharmaceuticals, Inc. from 2005-2013, where she led the transformation of the company into a biotechnology industry leader. Prior to Millennium, which became Takeda Oncology, Dr. Dunsire led the Novartis North America Oncology Business through a period of significant growth during her 10-year tenure. She also previously served as President and Chief Executive Officer of FORUM Pharmaceuticals and in a variety of R&D and Commercial positions with Sandoz AG. Dr. Dunsire currently serves as President and Chief Executive Officer of Xtuit Pharmaceuticals, Inc., a privately held biopharmaceutical company developing novel therapeutics.
Dr. Dunsire currently serves on the boards of Xtuit and Ultragenyx Pharmaceutical, Inc., a publicly traded biotechnology company. She previously served on the boards of Takeda Pharmaceuticals, Allergan, Inc., and FORUM Pharmaceuticals, Inc.
Dr. Dunsire is a member of the Leadership and Compensation Committee and the Science and Innovation Committee.